Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
Graftskin (Apligraf; Novartis Pharmaceuticals Corporation, East Hanover, NJ), a bilayered living skin construct, is approved in the United States for venous ulcers and diabetic foot ulcers.1-3 Studies suggest that Graftskin may also heal excisional wounds.4 Graftskin is approximately 0.075-cm thick, so it is structurally similar to a split-thickness skin graft. Graftskin can be meshed for better adherence to exudative wounds. Meshing of skin grafts may also promote healing by increasing dermal exposure to underlying tissue.5 Although Graftskin is frequently meshed in the clinical setting, there is little information as to how this affects the tissue. We examined the effects of manipulating and meshing Graftskin on its structural integrity and viability.
Jansen DA, Asgari MM, Atillasoy ES, Milstone LM. Clinical and In Vitro Responses of Bilayered Skin Construct (Graftskin) to Meshing. Arch Dermatol. 2002;138(6):843–844. doi:10.1001/archderm.138.6.838
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: